Newsletters

[Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (PR Newswire)] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its Phase III OptiTROP-Lung06 trial met its primary endpoint, with sac-TMT plus pembrolizumab significantly improving progression-free survival as a first-line treatment for PD-L1-negative advanced non-squamous NSCLC.

[Nature Communications] Researchers identified a Kat5-STAT6 epigenetic-metabolic axis that governs fibrotic progression. Kat5 directly acetylates STAT6 at lysine 636, thereby suppressing STAT6 dimerization, phosphorylation and nuclear translocation.

[Journal of the American Chemical Society] Scientists developed an inhalable dual-PROTAC nanotherapy that simultaneously degrades STING and BRD4, targeting epithelial senescence and fibroblast activation to reverse pulmonary fibrosis.

[NPJ Regenerative Medicine] The authors showed that retinoic acid induces endothelial angiogenesis, which is associated with enhanced paracrine signalling to alveolar epithelial cells.

[Inflammation and Regeneration] Researchers showed that alveolar type II cell therapy alleviates pulmonary fibrosis by reprogramming profibrotic macrophages and restoring a pro-repair lung immune microenvironment.

[Biogerontology] Scientists investigated whether emodin, a natural compound with known anti-aging properties, alleviates radiation-induced pulmonary fibrosis by suppressing radiation-induced cellular senescence.

[Cancer Cell] Researchers identified TROP2 as a vulnerability in drug-tolerant persister cells, showing that combining a TROP2-targeting antibody-drug conjugate with osimertinib delays resistance and tumor relapse in EGFR-mutant lung cancer.

[Cell Death & Disease] Investigators identified SUMO1 modification at lysine 128 of ECHS1 as an essential activation switch that drives mitochondrial catabolism and restricts growth of lung cancer cells.

[Archives of Toxicology] Scientists highlight chalcones as multitarget compounds for non-small cell lung cancer, reviewing their potential to modulate tumor signaling, epithelial–mesenchymal transition, and therapy resistance.

[EMBO Molecular Medicine] Researchers identified dermal papillary fibroblasts as drivers of persistent granulation tissue formation in junctional epidermolysis bullosa, revealing TGFβ signaling as a promising therapeutic target.

[Cell Reports] Scientists identified myeloid matrix metalloproteinase-14 as a key driver of obesity-associated inflammation and metabolic dysfunction, linking ECM remodeling to insulin resistance and fatty liver disease.

[Journal of Nanobiotechnology] The authors developed an ECM-mimetic injectable hydrogel that recreates a hypoxic microenvironment, reduces nucleus pulposus cell senescence, and promotes regeneration to slow intervertebral disc degeneration.